LUND, SWEDEN--(Marketwire - October 02, 2007) - Active Biotech AB (OMX Nordic:ACTI) today informs that MediGene AG (Frankfurt, Prime Standard: MDG) has been granted a US patent that covers the candidate drug RhuDex®. Patent no. 7,276,505 protects the substance RhuDex® (and related small molecules) and its pharmaceutical compositions. This pivotal patent adds to MediGene’s growing patent portfolio on related chemical compounds that support the mode of action of RhuDex®. MediGene is developing RhuDex® as a drug for the treatment of rheumatoid arthritis and is currently testing the drug in patients in a clinical phase IIa pilot trial.
